• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

叶酸载体和蛋白偶联叶酸转运体在非小细胞肺癌细胞中抗叶酸类药物蓄积的功能特征。

Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.

机构信息

Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China (Y.W., J.L., M.B., Z.M., S.M., S.Z.); Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China (J.L., H.J.); The Fourth College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China (Y.X.); and Shanghai AB SCIEX Analytical Instrument Trading Co., Ltd., Shanghai, China (D.L.).

Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China (Y.W., J.L., M.B., Z.M., S.M., S.Z.); Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China (J.L., H.J.); The Fourth College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China (Y.X.); and Shanghai AB SCIEX Analytical Instrument Trading Co., Ltd., Shanghai, China (D.L.)

出版信息

Drug Metab Dispos. 2024 Oct 16;52(11):1332-1344. doi: 10.1124/dmd.124.001872.

DOI:10.1124/dmd.124.001872
PMID:39261014
Abstract

Antifolates are important for chemotherapy in non-small cell lung cancer (NSCLC). They mainly rely on reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT) to enter cells. PCFT is supposed to be the dominant transporter of the two in tumors, as it operates optimally at acidic pH and has limited transport activity at physiological pH, whereas RFC operates optimally at neutral pH. In this study, we found RFC showed a slightly pH-dependent uptake of antifolates, with similar affinity values at pH 7.4 and 6.5. PCFT showed a highly pH-dependent uptake of antifolates, with an optimum pH of 6.0 for pemetrexed and 5.5 for methotrexate. The Michaelis-Menten constant ( ) value of PCFT for pemetrexed at pH 7.4 was more than 10 times higher than that at pH 6.5. Interestingly, we found that antifolate accumulations mediated by PCFT at acidic pH were significantly affected by the efflux transporter, breast cancer resistance protein (BCRP). The highest pemetrexed concentration was observed at pH 7.0-7.4 after a 60-minute accumulation in PCFT-expressing cells, which was further evidenced by the cytotoxicity of pemetrexed, with the value of pemetrexed at pH 7.4 being one-third of that at pH 6.5. In addition, the in vivo study indicated that increasing PCFT and RFC expression significantly enhanced the antitumor efficacy of pemetrexed despite the high expression of BCRP. These results suggest that both RFC and PCFT are important for antifolates accumulation in NSCLC, although there is an acidic microenvironment and high BCRP expression in tumors. SIGNIFICANCE STATEMENT: Evaluating the role of reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT) on antifolates accumulation in non-small cell lung cancer (NSCLC) is necessary for new drug designs. By using cell models, we found both RFC and PCFT were important for antifolates accumulation in NSCLC. Breast cancer resistance protein (BCRP) significantly affected PCFT-mediated antifolates accumulation at acidic pH but not RFC-mediated pemetrexed accumulation at physiological pH. High expression of PCFT or RFC enhanced the cytotoxicity and antitumor effect of pemetrexed.

摘要

叶酸拮抗剂在非小细胞肺癌(NSCLC)的化疗中非常重要。它们主要依靠还原叶酸载体(RFC)和质子偶联叶酸转运体(PCFT)进入细胞。PCFT 被认为是两种转运体在肿瘤中的主要转运体,因为它在酸性 pH 下最佳运作,在生理 pH 下转运活性有限,而 RFC 在中性 pH 下最佳运作。在这项研究中,我们发现 RFC 对叶酸拮抗剂的摄取表现出轻微的 pH 依赖性,在 pH 7.4 和 6.5 时具有相似的亲和力值。PCFT 对叶酸拮抗剂的摄取表现出高度的 pH 依赖性,培美曲塞的最佳 pH 为 6.0,甲氨蝶呤的最佳 pH 为 5.5。PCFT 在 pH 7.4 时对培美曲塞的米氏常数( )值比 pH 6.5 时高出 10 多倍。有趣的是,我们发现酸性 pH 下由 PCFT 介导的叶酸拮抗剂积累会受到外排转运蛋白乳腺癌耐药蛋白(BCRP)的显著影响。在 PCFT 表达细胞中孵育 60 分钟后,在酸性 pH 值下观察到最高的培美曲塞浓度,这进一步证明了培美曲塞的细胞毒性,pH 值为 7.4 时的 值是 pH 值为 6.5 时的三分之一。此外,体内研究表明,尽管 BCRP 高表达,增加 PCFT 和 RFC 的表达可显著增强培美曲塞的抗肿瘤疗效。这些结果表明,尽管肿瘤中存在酸性微环境和高 BCRP 表达,但 RFC 和 PCFT 对 NSCLC 中叶酸拮抗剂的积累都很重要。

相似文献

1
Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.叶酸载体和蛋白偶联叶酸转运体在非小细胞肺癌细胞中抗叶酸类药物蓄积的功能特征。
Drug Metab Dispos. 2024 Oct 16;52(11):1332-1344. doi: 10.1124/dmd.124.001872.
2
Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.叶酸转运体动力学以及经典和肿瘤靶向性抗叶酸药物治疗
Sci Rep. 2021 Mar 18;11(1):6389. doi: 10.1038/s41598-021-85818-x.
3
Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.通过质子偶联叶酸转运体靶向非鳞状非小细胞肺癌,使用6-取代的吡咯并[2,3-d]嘧啶噻吩甲酰抗叶酸剂。
Mol Pharmacol. 2016 Apr;89(4):425-34. doi: 10.1124/mol.115.102798. Epub 2016 Feb 2.
4
The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.主要促进叶酸转运蛋白溶质载体 19A1 和溶质载体 46A1:生物学及在癌症抗叶酸化疗中的作用。
Drug Metab Dispos. 2014 Apr;42(4):632-49. doi: 10.1124/dmd.113.055723. Epub 2014 Jan 6.
5
The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.质子偶联叶酸转运体:与还原型叶酸载体相比,对培美曲塞转运及抗叶酸活性的影响
Mol Pharmacol. 2008 Sep;74(3):854-62. doi: 10.1124/mol.108.045443. Epub 2008 Jun 4.
6
Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.主要易化型叶酸转运蛋白SLC19A1和SLC46A1的生物学特性
Curr Top Membr. 2014;73:175-204. doi: 10.1016/B978-0-12-800223-0.00004-9.
7
Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.还原叶酸载体功能丧失增强了新型抗叶酸药物的抗肿瘤活性,这些药物通过质子偶联叶酸转运体选择性摄取。
Mol Pharmacol. 2012 Oct;82(4):591-600. doi: 10.1124/mol.112.079004. Epub 2012 Jun 26.
8
Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.通过叶酸受体介导的内吞作用递送至细胞内的抗叶酸药物活性的决定因素。
Cancer Chemother Pharmacol. 2015 Jun;75(6):1163-73. doi: 10.1007/s00280-015-2733-8. Epub 2015 Apr 7.
9
The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.利用质子偶联叶酸转运蛋白选择性治疗癌症的前景与挑战。
Cancer Chemother Pharmacol. 2018 Jan;81(1):1-15. doi: 10.1007/s00280-017-3473-8. Epub 2017 Nov 10.
10
Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.培美曲塞耐药细胞系中缺乏叶酸特异性易化载体但叶酸受体表达增加的情况下,叶酸-去乙酰长春碱单水合物缀合物的增强的受体介导的内吞作用和细胞毒性。
Mol Pharmacol. 2014 Feb;85(2):310-21. doi: 10.1124/mol.113.089110. Epub 2013 Nov 18.